An announcement from Spero Therapeutics (SPRO) is now available.
Spero Therapeutics, Inc. stockholders have greenlit an expansion of the company’s 2017 Stock Incentive Plan, adding 3 million more shares available for issuance. Details on the plan’s specifics were outlined in the Proxy Statement for the 2024 Annual Meeting, emphasizing the company’s commitment to leveraging stock incentives for growth and rewarding performance.
See more data about SPRO stock on TipRanks’ Stock Analysis page.
